A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Oral Ozanimod as Maintenance Therapy for Moderately to Severely Active Crohn's Disease
Phase of Trial: Phase III
Latest Information Update: 05 Dec 2019
Price : $35 *
At a glance
- Drugs Ozanimod (Primary)
- Indications Crohn's disease
- Focus Registrational; Therapeutic Use
- Sponsors Celgene Corporation; Celgene International SARL
- 08 Oct 2019 Planned End Date changed from 31 May 2021 to 31 Aug 2021.
- 31 Jul 2019 Planned number of patients changed from 485 to 535.
- 07 Dec 2018 Planned End Date changed from 30 Apr 2021 to 31 May 2021.